631 578

Cited 2841 times in

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

 Eric Van Cutsem  ;  Claus-Henning Köhne  ;  Erika Hitre  ;  Jerzy Zaluski  ;  Chung-Rong Chang Chien  ;  Anatoly Makhson  ;  Geert D’Haens  ;  Tamás Pintér  ;  Robert Lim  ;  György Bodoky  ;  Jae Kyung Roh  ;  Gunnar Folprecht  ;  Paul Ruff  ;  Christopher Stroh  ;  Sabine Tejpar  ;  Michael Schlichting  ;  Johannes Nippgen  ;  Philippe Rougier 
 NEW ENGLAND JOURNAL OF MEDICINE, Vol.360(14) : 1408-1417, 2009 
Journal Title
Issue Date
Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/therapeutic use* ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Camptothecin/analogs & derivatives ; Camptothecin/therapeutic use ; Cetuximab ; Colorectal Neoplasms/drug therapy* ; Colorectal Neoplasms/genetics ; Disease Progression ; Female ; Fluorouracil/therapeutic use ; Genes, ras* ; Humans ; Kaplan-Meier Estimate ; Leucovorin/therapeutic use ; Male ; Middle Aged ; Mutation ; Neoplasm Metastasis/drug therapy ; Receptor, Epidermal Growth Factor/antagonists & inhibitors* ; Young Adult
BACKGROUND: We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought associations between the mutation status of the KRAS gene in tumors and clinical response to cetuximab. METHODS: We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab. The primary end point was progression-free survival. RESULTS: A total of 599 patients received cetuximab plus FOLFIRI, and 599 received FOLFIRI alone. The hazard ratio for progression-free survival in the cetuximab-FOLFIRI group as compared with the FOLFIRI group was 0.85 (95% confidence interval [CI], 0.72 to 0.99; P=0.048). There was no significant difference in the overall survival between the two treatment groups (hazard ratio, 0.93; 95% CI, 0.81 to 1.07; P=0.31). There was a significant interaction between treatment group and KRAS mutation status for tumor response (P=0.03) but not for progression-free survival (P=0.07) or overall survival (P=0.44). The hazard ratio for progression-free survival among patients with wild-type-KRAS tumors was 0.68 (95% CI, 0.50 to 0.94), in favor of the cetuximab-FOLFIRI group. The following grade 3 or 4 adverse events were more frequent with cetuximab plus FOLFIRI than with FOLFIRI alone: skin reactions (which were grade 3 only) (in 19.7% vs. 0.2% of patients, P<0.001), infusion-related reactions (in 2.5% vs. 0%, P<0.001), and diarrhea (in 15.7% vs. 10.5%, P=0.008). CONCLUSIONS: First-line treatment with cetuximab plus FOLFIRI, as compared with FOLFIRI alone, reduced the risk of progression of metastatic colorectal cancer. The benefit of cetuximab was limited to patients with KRAS wild-type tumors.
Files in This Item:
T200903283.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Roh, Jae Kyung(노재경)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.